{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:46:32Z","timestamp":1768214792722,"version":"3.49.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Premature twins face a dual challenge: a high incidence of hemodynamically significant patent ductus arteriosus (hsPDA) and a poor response to ibuprofen. Current management, derived from singleton data, fails to address this population's unique risks. Our study specifically investigates risk factors for hsPDA development and ibuprofen treatment failure in preterm twins to enable personalized prevention and therapy. Thus, the potential biomarkers for the occurrence of hsPDA and ibuprofen closure failure were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective case-control study. 736 twin infants born at \u226434 weeks of gestation were included, of which 70 were exposed to hsPDA and 66 were exposed to ibuprofen. Clinical data were obtained from the Electronic Medical Record system. For the occurrence of hsPDA and failure of ibuprofen treatment, multivariate logistic regression was employed to identify the independent risk factor and the potential biomarkers were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      1. When compared to the non-hsPDA group, the hsPDA group demonstrated markedly higher incidences of low birth weight, lower gestational age, male gender, low 5\u2005min Apgar scores, selective intrauterine growth restriction (sIUGR), use of pulmonary surfactant, respiratory distress syndrome (RDS), \u2265grade III intraventricular hemorrhage, and early-onset sepsis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). The hsPDA group had a notably higher rate of sIUGR (28.6%) relative to the non-hsPDA group (15.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). Furthermore, in twins with sIUGR, the larger infant exhibited a higher hsPDA incidence than the non-hsPDA group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). 2. Univariate analysis revealed that vaginal delivery, birth weight, gestational age, male gender, 5\u2005min Apgar score, early-onset sepsis, RDS, and sIUGR were associated with the occurrence of hsPDA (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Multivariate regression identified sIUGR [odds ratio (OR)\u2009=\u20093.337, 95% confidence interval (95% CI) 1.301\u20138.560] as an independent risk factor (IRF), while a higher birth weight (OR\u2009=\u20090.537, 95% CI 0.437\u20130.660) was noted to be a protective factor (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). 3. Compared with the successful treatment group, the treatment failure group showed higher rates of premature rupture of membranes (PROMs)\u2009&amp;gt;\u200918\u2005h, postnatal surfactant use, and monochorionic diamniotic (MCDA) twins (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0167, Bonferroni correction). The treatment failure group included 11 MCDA cases (73.3%), markedly more than the successful treatment group (33.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). 4. Univariate regression analysis identified gestational age, birth weight, MCDA, 5\u2005min Apgar score, and PROMs\u2009&amp;gt;\u200918\u2005h as factors associated with ibuprofen treatment failure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Multivariate regression revealed MCDA (OR\u2009=\u20094.686, 95% CI 1.070\u201320.530) and PROMs\u2009&amp;gt;\u200918\u2005h (OR\u2009=\u200915.198, 95% CI 2.377\u201397.178) as IRFs for ibuprofen treatment failure (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). 5. In the pharmacological closure group, MCDA twins exhibited markedly lower closure rates after both the first and total two courses compared to dichorionic diamniotic twins (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). MCDA twins required higher cumulative drug doses (40.21\u2009\u00b1\u20091.27 vs. 32.21\u2009\u00b1\u20090.53,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05), although no significant difference in the frequency of administration was detected. The MCDA group also had a higher rate of surgical interventions (39.29% vs. 10.53%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). 6. The NT-proBNP, Hs-cTn, PGE2, Cortisol, and TXA2 levels in the sIUGR group were markedly elevated versus those in the non-sIUGR group, with statistically significant differences (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In preterm twins \u226434 weeks, sIUGR is an IRF for hsPDA. In addition, MCDA and PROMs\u2009&amp;gt;\u200918\u2005h are IRFs for ibuprofen treatment failure. Meanwhile, elevated levels of NT-proBNP and Hs-cTn may play a role in the development of hsPDA in preterm infants with sIUGR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1687361","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:51:45Z","timestamp":1768204305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for hemodynamically significant patent ductus arteriosus and ibuprofen treatment failure in premature twins: a retrospective case-control study"],"prefix":"10.3389","volume":"12","author":[{"given":"Bo","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","first-page":"1","article-title":"Births: final data for 2022","volume":"73","author":"Osterman","year":"2024","journal-title":"Natl Vital Stat Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1226","DOI":"10.1016\/s2214-109x(21)00298-9","article-title":"Preterm births in China between 2012 and 2018: an observational study of more than 9 million women","volume":"9","author":"Deng","year":"2021","journal-title":"Lancet Glob Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12884-018-2082-9","article-title":"Perinatal outcomes in twin pregnancies complicated by maternal morbidity: evidence from the WHO multicountry survey on maternal and newborn health","volume":"18","author":"Santana","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e70549","DOI":"10.1371\/journal.pone.0070549","article-title":"Maternal and perinatal outcomes of twin pregnancy in 23 low- and middle-income countries","volume":"8","author":"Vogel","year":"2013","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1161\/circulationaha.113.002453","article-title":"Increased prevalence of congenital heart defects in monozygotic and dizygotic twins","volume":"128","author":"Herskind","year":"2013","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1055\/s-0030-1247597","article-title":"Outcomes and milestone achievement differences for very low-birth-weight multiples compared with singleton infants","volume":"27","author":"Kirkby","year":"2010","journal-title":"Am J Perinatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00246-021-02765-0","article-title":"Ductus arteriosus of extremely preterm twins is more resistant to cyclooxygenase inhibitors than those of singletons","volume":"43","author":"Ono","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/uog.19013","article-title":"Consensus definition and essential reporting parameters of selective fetal growth restriction in twin pregnancy: a Delphi procedure","volume":"53","author":"Khalil","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jpeds.2012.03.012","article-title":"Hemodynamic effects of fluid restriction in preterm infants with significant patent ductus arteriosus","volume":"161","author":"De Buyst","year":"2012","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pedneo.2015.04.017","article-title":"Repeated courses of oral ibuprofen in premature infants with patent ductus arteriosus: efficacy and safety","volume":"58","author":"Olgun","year":"2017","journal-title":"Pediatr Neonatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2020-1209","article-title":"Patent ductus arteriosus of the preterm infant","volume":"146","author":"Hamrick","year":"2020","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/archdischild-2022-324111","article-title":"Ductus arteriosus and the preterm brain","volume":"108","author":"Chock","year":"2023","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B13","doi-asserted-by":"publisher","first-page":"151717","DOI":"10.1016\/j.semperi.2023.151717","article-title":"Association of patent ductus arteriosus with fetal factors and endotypes of prematurity","volume":"47","author":"Villamor","year":"2023","journal-title":"Semin Perinatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1080\/14767058.2016.1219991","article-title":"Prevalence and risk factors associated with the patency of ductus arteriosus in premature neonates: a prospective observational study from Iran","volume":"30","author":"Pourarian","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/14767058.2020.1757060","article-title":"The impact of chorionicity and assisted reproductive therapies in obstetric and neonatal outcomes","volume":"35","author":"Ferraz Liz","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000442968","article-title":"Very low birth weight monochorionic diamniotic twins as a risk factor for symptomatic patent ductus arteriosus","volume":"109","author":"Yamaguchi","year":"2016","journal-title":"Neonatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1542\/peds.2008-1117","article-title":"Genetic contribution to patent ductus arteriosus in the premature newborn","volume":"123","author":"Bhandari","year":"2009","journal-title":"Pediatrics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.tjog.2021.03.023","article-title":"Association between intrauterine growth restriction and patent ductus arteriosus: use of a dichorionic twin pregnancy model","volume":"60","author":"Yang","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41372-019-0427-5","article-title":"Birth weight discordance in very low birth weight twins: mortality, morbidity, and neurodevelopment","volume":"39","author":"Boghossian","year":"2019","journal-title":"J Perinatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/14767058.2010.509920","article-title":"Patent ductus arteriosus in the preterm infant: new insights into pathogenesis and clinical management","volume":"23","author":"Antonucci","year":"2010","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"F45","DOI":"10.1136\/adc.2009.168682","article-title":"Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants","volume":"96","author":"Jones","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00431-018-3086-1","article-title":"Effect on cerebral oxygenation of paracetamol for patent ductus arteriosus in preterm infants","volume":"177","author":"Dani","year":"2018","journal-title":"Eur J Pediatr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00431-016-2830-7","article-title":"Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates","volume":"176","author":"El-Mashad","year":"2017","journal-title":"Eur J Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"Cd013588","DOI":"10.1002\/14651858.CD013588.pub2","article-title":"Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of cochrane systematic reviews","volume":"4","author":"Mitra","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0138114","DOI":"10.1371\/journal.pone.0138114","article-title":"Chorioamnionitis and patent ductus arteriosus: a systematic review and meta-analysis","volume":"10","author":"Park","year":"2015","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.pedneo.2022.09.015","article-title":"Predictors of a non-response to prophylactic indomethacin for patent ductus arteriosus in preterm infants","volume":"64","author":"Utsumi","year":"2023","journal-title":"Pediatr Neonatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/s0022-3476(80)80337-4","article-title":"The ductus arteriosus in the preterm infant: histologic and clinical observations","volume":"96","author":"Gittenberger-de Groot","year":"1980","journal-title":"J Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s12576-017-0565-5","article-title":"Attenuation of ductus arteriosus intimal thickening in preterm sheep twins compared with singletons","volume":"67","author":"Ito","year":"2017","journal-title":"J Physiol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41372-018-0192-x","article-title":"High-sensitivity troponin T in preterm infants with a hemodynamically significant patent ductus arteriosus","volume":"38","author":"Asrani","year":"2018","journal-title":"J Perinatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.earlhumdev.2016.12.007","article-title":"Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants","volume":"105","author":"Weisz","year":"2017","journal-title":"Early Hum Dev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/jp.2015.33","article-title":"Predictors of successful closure of patent ductus arteriosus with indomethacin","volume":"35","author":"Ahamed","year":"2015","journal-title":"J Perinatol"},{"key":"B32","first-page":"E141","article-title":"N-Terminal pro-brain natriuretic peptide levels in dichorionic diamniotic twins with selective intrauterine growth restriction","volume":"59","author":"Fujioka","year":"2014","journal-title":"Kobe J Med Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/jp.2013.119","article-title":"N-terminal pro-brain natriuretic peptide levels in monochorionic diamniotic twins with selective intrauterine growth restriction","volume":"34","author":"Fujioka","year":"2014","journal-title":"J Perinatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1515\/jpm.2011.065","article-title":"Natriuretic peptide levels in intrauterine growth-restricted fetuses with absent and reversed end-diastolic flow of the umbilical artery in relation to ductus venosus flow velocities","volume":"39","author":"Bahlmann","year":"2011","journal-title":"J Perinat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1203\/01.Pdr.0000061564.86797.78","article-title":"Cardiac hypertrophy and altered hemodynamic adaptation in growth-restricted preterm infants","volume":"53","author":"Leip\u00e4l\u00e4","year":"2003","journal-title":"Pediatr Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/jp.2012.94","article-title":"B-type natriuretic peptide levels are correlated with birth-weight discordance in monochorionic-diamniotic twins without twin-twin transfusion syndrome","volume":"33","author":"Moriichi","year":"2013","journal-title":"J Perinatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/jp.2011.136","article-title":"Renin is activated in monochorionic diamniotic twins with birthweight discordance who do not have twin-to-twin transfusion syndrome","volume":"32","author":"Fujioka","year":"2012","journal-title":"J Perinatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nm.2060","article-title":"Platelets contribute to postnatal occlusion of the ductus arteriosus","volume":"16","author":"Echtler","year":"2010","journal-title":"Nat Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1687361\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:51:47Z","timestamp":1768204307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1687361\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2025.1687361"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1687361","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1687361"}}